FS069 ultrasound contrast agent data

MB announced positive results of its Phase III study of 203 patients who were scheduled for diagnostic ultrasound examinations of the heart. Enrolled patients were required to have at least 33 percent of left ventricular borders not visible on the baseline echocardiogram.

End points were the ability of FS069 and MB's first generation contrast agent, Albunex, to provide left ventricular opacification (LVO) and improvement in endocardial border delineation (EBD), as well as to enhance Doppler signals. LVO measures the ability of a contrast agent to fill the left ventricle. EBD measures the ability to see wall motion abnormalities. Doppler signals are used to study cardiac hemodynamics and valvular heart disease. ...